/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

INMUNE BIO INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.76 0.121(12.1%) INMB at 04 Dec 2025 04:35 PM Biotechnology
Lowest Today 1.54
Highest Today 1.79
Today’s Open 1.56
Prev. Close 1.57
52 Week High 10.50
52 Week Low 1.38
Day’s Range: Low 1.54 High 1.79
52-Week Range: Low 1.38 High 10.50
1 day return -
1 Week return +2.31
1 month return +2.6
3 month return -7.32
6 month return -76.81
1 year return -65.01
3 year return -73.58
5 year return -80.43
10 year return -

Institutional Holdings

BlackRock Inc 4.41

Vanguard Group Inc 3.19

Vanguard Total Stock Mkt Idx Inv 1.80

UBS Group AG 1.69

iShares Russell 2000 ETF 1.53

Geode Capital Management, LLC 1.47

State Street Corp 1.04

Dauntless Investment Group, LLC 0.93

Rhenman Healthcare Equity L/S RC2 SEK 0.67

Rhenman Partners Asset Management AB 0.67

Fidelity Small Cap Index 0.63

Northern Trust Corp 0.62

Vanguard Institutional Extnd Mkt Idx Tr 0.57

iShares Russell 2000 Growth ETF 0.55

XTX Topco Ltd 0.47

Morgan Stanley - Brokerage Accounts 0.39

Fidelity Extended Market Index 0.32

Vanguard Russell 2000 ETF 0.30

JPMorgan Chase & Co 0.28

SIMPLEX TRADING, LLC 0.26

Bank of New York Mellon Corp 0.23

Charles Schwab Investment Management Inc 0.19

Buckingham Strategic Partners 0.18

Royal Bank of Canada 0.18

Mccormack Advisors International 0.18

Scientech Research LLC 0.17

LPL Financial Corp 0.16

Millennium Management LLC 0.16

State St Russell Sm Cap® Indx SL Cl I 0.16

Schwab Small Cap Index 0.16

NT R2000 Index Fund - NL 0.15

Extended Equity Market Fund K 0.14

iShares Micro-Cap ETF 0.14

SPDR® Russell 2000 US Small Cap ETF 0.13

NT R2000 Index Fund - DC - NL - 3 0.12

Russell 2500™ Index Fund F 0.12

Fidelity Total Market Index 0.11

iShares Russell 2000 Small-Cap Idx Instl 0.09

Fidelity Series Total Market Index 0.08

Russell 2000 Index Non-Lendable Fund E 0.08

Market Status

Strong Buy: 2

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 41.74 M

PB Ratio 1.6447

PE Ratio 0.0

Enterprise Value 15.08 M

Total Assets 39.56 M

Volume 503040

Company Financials

Annual Revenue FY23:224000 0.2M, FY22:374000 0.4M, FY21:181000 0.2M, FY20:10916 0.0M, FY19:77688000 77.7M

Annual Profit FY23:null 0.0M, FY22:374000 0.4M, FY21:181000 0.2M, FY20:10916 0.0M, FY19:77688000 77.7M

Annual Net worth FY23:-27433000 -27.4M, FY22:-28647000 -28.6M, FY21:-30340000 -30.3M, FY20:-12099159 -12.1M, FY19:-9142625 -9.1M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:50000 0.1M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-28000 -0.0M, Q2/2025:null 0.0M, Q1/2025:50000 0.1M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-6472000 -6.5M, Q2/2025:-24458000 -24.5M, Q1/2025:-9739000 -9.7M, Q3/2024:-12093000 -12.1M, Q2/2024:-9746000 -9.7M

Fund house & investment objective

Company Information INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Organisation Biotechnology

Employees 13

Industry Biotechnology

CEO Mr. David J. Moss M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow